RJ

Rabbani Jilani Shaikh

Active Director Director DIN 11046723
DIN 11046723 First appointment Apr 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Rabbani Jilani Shaikh

Data last updated:

Rabbani Jilani Shaikh is a Director at Zybernetics Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11046723
Primary Designation Director
Industry Pharma
First Appointment 09 Apr 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director09 Apr 20252025Active

Directorship timeline

Open interactive timeline →
Zybernetics Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rabbani Jilani Shaikh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rabbani Jilani Shaikh

Rabbani Jilani Shaikh currently holds 1 directorship: Zybernetics Pharmaceuticals Private Limited (Director, since 09 Apr 2025).

Rabbani Jilani Shaikh was first appointed on 09 Apr 2025 as Director at Zybernetics Pharmaceuticals Private Limited.

The current boards of Rabbani Jilani Shaikh's companies include Altaf Ibrahim Patel (Zybernetics Pharmaceuticals Private Limited), Bhikh Singh Devda (Zybernetics Pharmaceuticals Private Limited), Dilip Patel (Zybernetics Pharmaceuticals Private Limited), Prasad Ramachandran Nair (Zybernetics Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available